Wouter Joustra MSc
General Partner
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.
Industry
Biotech
Status
Current
Location
UK
Our mission is to transform lives by accelerating innovation in cardiometabolic health. We’re advancing multiple product candidates through the drug development pathway, and Forbion’s backing has allowed us to navigate each step with conviction. Their investment has helped us scale strategically while staying aligned with our long-term, patient-focussed vision.Khurem Farooq
CEO
$411m
Europe’s largest known Series A funding round
Forbion team